<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093197</url>
  </required_header>
  <id_info>
    <org_study_id>KAI-9803-001</org_study_id>
    <nct_id>NCT00093197</nct_id>
  </id_info>
  <brief_title>Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack</brief_title>
  <official_title>Intracoronary KAI-9803 for Injection as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KAI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KAI Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Restoring blood flow to coronary arteries as quickly as possible is the best way to reduce&#xD;
      the damage to the muscle that occurs with a heart attack. However, up to 25-50% of patients&#xD;
      who have angioplasty may have ongoing damage to the heart muscle when the blockage is opened&#xD;
      and blood flow is restored. Complications which may result from this ongoing damage include a&#xD;
      larger area of damaged muscle in the heart, enlargement of the heart, an increased risk of&#xD;
      death, and an increased risk of heart failure. Some of the ongoing damage may involve&#xD;
      increased levels of the protein kinase C (PKC) enzyme. KAI-9803 is a selective inhibitor of&#xD;
      delta PKC. In this study, delta PKC is used with angioplasty and other standard procedures to&#xD;
      restore blood flow after a heart attack. This study is designed to evaluate safety of&#xD;
      different amounts of KAI-9803 when used in treating heart attack patients undergoing&#xD;
      angioplasty. We will also try to evaluate whether KAI-9803 can reduce the amount of heart&#xD;
      muscle damage and the complications that may occur in these patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with major cardiac events (death, congestive heart failure, recurrent myocardial infarction, repeat target vessel revascularization)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Creatine kinase-myocardial band (CK-MB)</measure>
    <time_frame>7 days or hospitalization discharge, whichever occurs first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST-segment elevation</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiography vessel flow</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct size by single photon emission computed tomography (SPECT)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic left ventricular ejection fraction (LVEF)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>A1: KAI-9803</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A2: KAI-9803</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A3: KAI-9803</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A4: KAI-9803</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A5: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAI-9803 for Injection</intervention_name>
    <description>0.05 mg</description>
    <arm_group_label>A1: KAI-9803</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAI-9803 for Injection</intervention_name>
    <description>0.5 mg</description>
    <arm_group_label>A2: KAI-9803</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAI-9803 for Injection</intervention_name>
    <description>1.25 mg</description>
    <arm_group_label>A3: KAI-9803</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAI-9803 for Injection</intervention_name>
    <description>5 mg</description>
    <arm_group_label>A4: KAI-9803</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>A5: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptoms of cardiac ischemia at rest or with increasing frequency (angina or angina&#xD;
             equivalent), with episodes lasting for at least 30 minutes within 6 hours of&#xD;
             presentation&#xD;
&#xD;
          -  Persistent ST-segment elevation of â‰¥ 0.2 mV in at least 2 contiguous precordial leads&#xD;
             indicative of anterior Myocardial Infarction (MI) location (leads V1-V4)&#xD;
&#xD;
          -  At least 18 years old&#xD;
&#xD;
          -  Complete occlusion of the left anterior descending artery (Thrombolysis in Myocardial&#xD;
             Infarction (TIMI) 0-1 flow) demonstrated on the initial angiogram&#xD;
&#xD;
          -  Culprit lesion suitable for primary percutaneous coronary intervention (PCI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any left bundle branch block (new or old), intraventricular conduction defect, or&#xD;
             paced rhythm that would obscure the diagnosis of acute anterior ST Elevation&#xD;
             Myocardial Infarction (STEMI)&#xD;
&#xD;
          -  Any prior documented myocardial infarction (MI), including old Q waves documented on&#xD;
             prior ECGs or a clinical history of definite MI&#xD;
&#xD;
          -  Any prior coronary artery bypass grafting (CABG)&#xD;
&#xD;
          -  Cardiogenic shock at initial hospital presentation, consisting of persistent&#xD;
             hypotension (systolic blood pressure &lt; 90 mm Hg for &gt; 20 minutes) and signs of&#xD;
             end-organ dysfunction (oliguria, altered mental status, poor peripheral perfusion, and&#xD;
             lactic acidosis)&#xD;
&#xD;
          -  TIMI grade 2 or 3 flow in the left anterior descending artery documented on the&#xD;
             initial diagnostic angiogram&#xD;
&#xD;
          -  Culprit lesion in the left anterior descending artery that is not suitable for primary&#xD;
             PCI&#xD;
&#xD;
          -  Treatment with intravenous fibrinolytic therapy (i.e. alteplase, reteplase,&#xD;
             tenecteplase, or streptokinase) within the 24 hours before presentation&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Know baseline creatinine &gt; 2.5 mg/dL without renal dialysis/renal replacement therapy&#xD;
             within the 30 days before presentation&#xD;
&#xD;
          -  Inability to comply with study procedures, inability to undergo cardiac&#xD;
             catheterization or primary percutaneous coronary intervention (PCI)&#xD;
&#xD;
          -  Participation in a study of experimental therapy (drug or device) within 30 days of&#xD;
             presentation, or prior participation in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duke Clinical Research Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>October 4, 2004</study_first_submitted>
  <study_first_submitted_qc>October 6, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2004</study_first_posted>
  <last_update_submitted>August 31, 2011</last_update_submitted>
  <last_update_submitted_qc>August 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

